Evaxion Biotech Files April 2025 6-K Report

TL;DR

Evaxion Biotech filed its April 6-K, incorporating prior filings. No new material info.

AI Summary

Evaxion Biotech A/S filed a Form 6-K on April 29, 2025, to report for the month of April 2025. The filing incorporates by reference previous registration statements on Forms S-8 and F-3, as well as multiple amended Form F-1 filings. The company is a foreign private issuer incorporated in G7 with its principal executive offices located at Dr. Neergaards Vej 5f, DK-2970 Hoersholm, Denmark.

Why It Matters

This filing serves as an update for Evaxion Biotech A/S, incorporating previous registration statements and providing information relevant to its ongoing reporting obligations as a foreign private issuer.

Risk Assessment

Risk Level: low — This is a routine reporting form (6-K) that incorporates previous filings, indicating no new significant events or disclosures.

Key Players & Entities

• Evaxion Biotech A/S (company) — Registrant
• Dr. Neergaards Vej 5f, DK-2970 Hoersholm, Denmark (location) — Principal executive offices
• 001-39950 (other) — Commission File Number
• 333-255064 (other) — Form S-8 File Number
• 333-265132 (other) — Form F-3 File Number
• 333-266050 (other) — Amended Form F-1 File Number
• 333-276505 (other) — Form F-1 File Number
• 333-279153 (other) — Form F-1 File Number
• 333-283304 (other) — Form F-1 File Number
• 333-285778 (other) — Form F-3 File Number

FAQ

From the Filing

0001171843-25-002574.txt : 20250429 0001171843-25-002574.hdr.sgml : 20250429 20250429083032 ACCESSION NUMBER: 0001171843-25-002574 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20250429 FILED AS OF DATE: 20250429 DATE AS OF CHANGE: 20250429 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Evaxion Biotech A/S CENTRAL INDEX KEY: 0001828253 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: G7 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39950 FILM NUMBER: 25882828 BUSINESS ADDRESS: STREET 1: DR NEERGAARDS VEJ 5F CITY: HOERSHOLM STATE: G7 ZIP: 2970 BUSINESS PHONE: 4552656554 MAIL ADDRESS: STREET 1: DR NEERGAARDS VEJ 5F CITY: HOERSHOLM STATE: G7 ZIP: 2970 6-K 1 f6k_042925.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025 Commission File Number: 001-39950 Evaxion Biotech A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐ INCORPORATION BY REFERENCE This report on Form 6-K shall be deemed to be incorporated by reference in Evaxion Biotech A/S’s (the “Company”) registration statements on Form S-8 (File No. 333-255064), on Form F-3 (File No. 333-265132), on Form F-1, as amended (File No. 333-266050), Form F-1 (File No. 333-276505), Form F-1 (File No. 333-279153), Form F-1 (File No. 333-283304), and Form F-3 (File No. 333- 285778), including any prospectuses forming a part of such registration statements and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. Amendment to Articles of Association Warrant Grants On March 19, 2025, the Company’s board of directors ascertained that the number of warrants granted February 6, 2025 to the directors, members of management and employees of the Company is calculated to be 1,372,407, rather than 1,367,199 warrants (the “Warrants”). Therefore, Article 2.5.13 of the Articles of Association was updated to provide for the grant of an additional 5,208 Warrants. Each Warrant confers the right to subscribe for one ordinary share of the Company at an exercise price equal to US $0.073 per share, converted into DKK using the official exchange rate between DKK and USD on the date of exercise; however no less than DKK 0.25 per share of nominal DKK 0.25 and provided, however, that the adjustment mechanisms in clause 6 of Appendix 5 to the Articles of Association may result in a different subscription price. The Warrants were issued on the terms and conditions set out in Appendix 5 of the Company’s Articles of Association. These Warrants vest with 1/12 per month from January 1, 2025. After giving effect to the grant of the Warrants described above, warrants to subscribe for an additional 36,473,753 ordinary shares of the Company remain available for future grant by the Company’s board of directors pursuant to article 2.5 of the Company’s Articles of Association. The foregoing description of the material terms of the Warrants is qualified in its entirety by reference to the Company’s Articles of Association, which is included as Exhibit 1.1 hereto and incorporated by reference herein. Warrant Amendments The Company has agreed with certain investors to convert the subscription price for 48,883,500 warrants representing ordinary shares from USD to DKK. The warrants were granted on 30 January 2025. It was agreed that: the subscription price